Evoke Pharma, Inc.
EVOK Real Time Price USDRecent trades of EVOK by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by EVOK's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Nasal formulations of metoclopramide Nov. 14, 2023
-
Patent Title: Nasal formulations of metoclopramide Apr. 18, 2023
-
Patent Title: Treatment of moderate and severe gastroparesis Dec. 06, 2022
-
Patent Title: Nasal formulations of metoclopramide Jun. 01, 2021
-
Patent Title: Nasal formulations of metoclopramide Dec. 18, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of EVOK in WallStreetBets Daily Discussion
Recent insights relating to EVOK
Recent picks made for EVOK stock on CNBC
ETFs with the largest estimated holdings in EVOK
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view EVOK Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.